78 related articles for article (PubMed ID: 8021743)
1. Adaptive control with feedback of suramin using intermittent infusions.
Figg WD; Stevens JA; Cooper MR
J Clin Oncol; 1994 Jul; 12(7):1523-4. PubMed ID: 8021743
[No Abstract] [Full Text] [Related]
2. Suramin: development of a population pharmacokinetic model and its use with intermittent short infusions to control plasma drug concentration in patients with prostate cancer.
Jodrell DI; Reyno LM; Sridhara R; Eisenberger MA; Tkaczuk KH; Zuhowski EG; Sinibaldi VJ; Novak MJ; Egorin MJ
J Clin Oncol; 1994 Jan; 12(1):166-75. PubMed ID: 8270974
[TBL] [Abstract][Full Text] [Related]
3. Suramin and hydrocortisone: determining drug efficacy in androgen-independent prostate cancer.
Kelly WK; Scher HI; Mazumdar M; Pfister D; Curley T; Leibertz C; Cohen L; Vlamis V; Dnistrian A; Schwartz M
J Clin Oncol; 1995 Sep; 13(9):2214-22. PubMed ID: 7666079
[TBL] [Abstract][Full Text] [Related]
4. Phase I study of suramin given by intermittent infusion without adaptive control in patients with advanced cancer.
Kobayashi K; Vokes EE; Vogelzang NJ; Janish L; Soliven B; Ratain MJ
J Clin Oncol; 1995 Sep; 13(9):2196-207. PubMed ID: 7666078
[TBL] [Abstract][Full Text] [Related]
5. Suramin for breast and prostate cancer: a pilot study of intermittent short infusions without adaptive control.
Woll PJ; Ranson M; Margison J; Thomson Y; van der Water L; George N; Howell A
Ann Oncol; 1994 Sep; 5(7):597-600. PubMed ID: 7993834
[TBL] [Abstract][Full Text] [Related]
6. Development and validation of a pharmacokinetically based fixed dosing scheme for suramin.
Reyno LM; Egorin MJ; Eisenberger MA; Sinibaldi VJ; Zuhowski EG; Sridhara R
J Clin Oncol; 1995 Sep; 13(9):2187-95. PubMed ID: 7666077
[TBL] [Abstract][Full Text] [Related]
7. Prospective evaluation of hydrocortisone and suramin in patients with androgen-independent prostate cancer.
Kelly WK; Curley T; Leibretz C; Dnistrian A; Schwartz M; Scher HI
J Clin Oncol; 1995 Sep; 13(9):2208-13. PubMed ID: 7545218
[TBL] [Abstract][Full Text] [Related]
8. Phase I and clinical evaluation of a pharmacologically guided regimen of suramin in patients with hormone-refractory prostate cancer.
Eisenberger MA; Sinibaldi VJ; Reyno LM; Sridhara R; Jodrell DI; Zuhowski EG; Tkaczuk KH; Lowitt MH; Hemady RK; Jacobs SC
J Clin Oncol; 1995 Sep; 13(9):2174-86. PubMed ID: 7666076
[TBL] [Abstract][Full Text] [Related]
9. Suramin: is adaptive control necessary?
Kobayashi K; Vokes EE; Stefansson K; Janisch L; Vogelzang NJ; Berezin F; Ratain MJ
J Clin Oncol; 1992 Dec; 10(12):1984-5; author reply 1985-6. PubMed ID: 1453214
[No Abstract] [Full Text] [Related]
10. Adaptive control with feedback strategies for suramin dosing.
Cooper MR; Lieberman R; La Rocca RV; Gernt PR; Weinberger MS; Headlee DJ; Kohler DR; Goldspiel BR; Peck CC; Myers CE
Clin Pharmacol Ther; 1992 Jul; 52(1):11-23. PubMed ID: 1623689
[TBL] [Abstract][Full Text] [Related]
11. Suramin for prostatic cancer: a phase I/II study in advanced extensively pretreated disease.
Van Oosterom AT; De Smedt EA; Denis LJ; de Bruijn EA; Mahler C
Eur J Cancer; 1990 Apr; 26(4):422. PubMed ID: 2141506
[No Abstract] [Full Text] [Related]
12. Feasibility and pharmacokinetics of intraperitoneal suramin in advanced malignancy.
Westermann AM; Dubbelman R; Baars JP; Moolenaar WH; Beijnen JH; Rodenhuis S
Cancer Chemother Pharmacol; 2000; 46(1):57-62. PubMed ID: 10912579
[TBL] [Abstract][Full Text] [Related]
13. A phase I study of suramin with once- or twice-monthly dosing in patients with advanced cancer.
Ryan CW; Vokes EE; Vogelzang NJ; Janisch L; Kobayashi K; Ratain MJ
Cancer Chemother Pharmacol; 2002 Jul; 50(1):1-5. PubMed ID: 12111104
[TBL] [Abstract][Full Text] [Related]
14. Evidence of an absorption phase after short intravenous suramin infusions.
Hutson PR; Tutsch K; Spriggs D; Christian M; Rago R; Mutch R; Wilding G
Cancer Chemother Pharmacol; 1993; 31(6):495-9. PubMed ID: 8453691
[TBL] [Abstract][Full Text] [Related]
15. Phase I study of suramin administered by intermittent infusion without adaptive control to cancer patients: update of two expanded dose levels near the maximally tolerated dose.
Kobayashi K; Vokes EE; Vogelzang NJ; Janisch L; Soliven B; Ratain MJ
J Clin Oncol; 1996 Sep; 14(9):2622-3. PubMed ID: 8823342
[No Abstract] [Full Text] [Related]
16. Suramin and prostate cancer: where do we go from here?
Clark JW; Chabner BA
J Clin Oncol; 1995 Sep; 13(9):2155-7. PubMed ID: 7666073
[No Abstract] [Full Text] [Related]
17. Suramin.
Eisenberger MA; Reyno LM
Cancer Treat Rev; 1994 Jul; 20(3):259-73. PubMed ID: 8020006
[No Abstract] [Full Text] [Related]
18. Pharmacometric analysis of the effect of furosemide on suramin pharmacokinetics.
Piscitelli SC; Forrest A; Lush RM; Ryan N; Whitfield LR; Figg WD
Pharmacotherapy; 1997; 17(3):431-7. PubMed ID: 9165547
[TBL] [Abstract][Full Text] [Related]
19. Suramin: rapid loading and weekly maintenance regimens for cancer patients.
van Rijswijk RE; van Loenen AC; Wagstaff J; Meijer E; Lopez R; van Groeningen CJ; Heimans JJ; Pinedo HM
J Clin Oncol; 1992 Nov; 10(11):1788-94. PubMed ID: 1403059
[TBL] [Abstract][Full Text] [Related]
20. Suramin: here to stay!?
Scher HI
J Natl Cancer Inst; 1993 Apr; 85(8):594-7. PubMed ID: 8468713
[No Abstract] [Full Text] [Related]
[Next] [New Search]
